Castomize
Singapore-based medtech startup developing 4D-printed orthopedic casts and splints using heat-moldable smart materials
- CEO / Founder
- Abel Teo
- Team Size
- 1-10
- Stage
- Growth Stage
- Total Funding
- $580K
- Latest Round
- Seed
- Key Investors
- Singapore University of Technology & Design (SUTD); VentureBlick; Co11ab; National Healthcare Group Centre for Medical Technologies & Innovations (CMTi); K-Startup Grand Challenge (grant)
Technology & Products
Key Products
Short Arm Cast, Long Arm Cast, Ankle Cast/Splint, Split Conversion Kit (coming soon), Prosthetics, Pet Health products
Technological Advantage
Proprietary 4D-printing technology using smart thermoplastics that change shape in response to temperature; standard sizes (no 3D scanning needed) reducing production time and cost; in-built removable clips eliminating cast saws
Differentiation
Value Proposition
4D-printed orthopedic casts that are breathable, waterproof, lightweight, and heat-moldable for custom fit, with reusable and adjustable capabilities throughout the healing process
How They Differentiate
Uses 4D-printing (smart materials that adapt post-manufacture) rather than standard 3D-printing; standard sizes instead of patient-specific 3D scanning; heat-moldable and reusable; eliminates cast saws with clip-on design
Market & Competition
Target Customers
Hospitals, orthopedic clinics, medical device distributors, and patients with limb fractures
Industry Verticals
Orthopedics, Physiotherapy, Prosthetics, Veterinary Health
Competitors
Icarus Medical (3D-printed knee braces); Spentys (3D-printed orthopedic casts); Ossiform (3D-printed implants)
Growth & Milestones
Growth Metrics
Regulatory clearance in Singapore, South Korea, Australia, and Taiwan as of May 2026; clinical trials at Tan Tock Seng Hospital; casts cost ~$25 to manufacture
Major Milestones
2022: Company founded as SUTD spin-off; 2024: Secured S$580K seed funding, entered South Korean market, Forbes 30 Under 30 Asia recognition; 2025: Regulatory approvals in Singapore and Korea; 2026: Cleared in Australia and Taiwan, FDA and CE mark applications in process
Notable Customers
Tan Tock Seng Hospital (clinical trials); medical supply distributors in South Korea